GeneDx Holdings Corp. (WGS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at GeneDx Holdings Corp..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 11 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 65.10 $ — 23% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 25.6% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 6
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.06 | -0.69 – 0.09 | 478 | -104.6% | 8 |
| 12/31/2027 | 1.10 | 0.41 – 1.91 | 595 | 1,831.4% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.19 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.20 | – | 96 | 66.60 | 5.70 | -3 | -6 |
| 2025: Q1 | -0.23 | – | 87 | 39.60 | -7.50 | 10 | 4 |
| 2025: Q2 | 0.36 | – | 103 | 45.60 | 10.50 | 10 | 8 |
| 2025: Q3 | -0.27 | – | 117 | 51.90 | -6.50 | 16 | 10 |
| 2025: Q4 | -0.66 | -426.10 | 121 | 26.50 | -14.60 | -3 | -7 |
| 2026: Q1 | -2.16 | – | 102 | 17.40 | -61.90 | -32 | -39 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 196 | -30 | -30 | -5.28 | -19 | – | – |
| 2020 | 179 | -242 | -241 | -42.89 | -93 | 4 | 252 |
| 2021 | 212 | -446 | -245 | -74.93 | -190 | 388 | 554 |
| 2022 | 235 | -668 | -549 | -53.63 | -319 | 254 | 545 |
| 2023 | 203 | -181 | -176 | -7.23 | -180 | 228 | 419 |
| 2024 | 305 | -23 | -52 | -1.94 | -29 | 245 | 419 |
| 2025 | 428 | -12 | -21 | -0.78 | 33 | 308 | 570 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
GeneDx Holdings Corp., ein Genomikunternehmen, bietet Gentestdienstleistungen an.
| Employees | 1,300 |
|---|---|
| Headquarters | Stamford, CT |
| Address | North Tower, 06902 Stamford, United States |
| Phone | 888 729 1206 |
| Website | genedx.com |
| IPO Date | 4. Nov 2020 |
| ISIN | US81663L2007 |
| Stock Split | 1:33 on 05/04/2023 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Katherine A. Stueland | CEO & Director | 1976 |
| Kevin Feeley CPA | Chief Financial Officer | 1981 |
| Bryan M. Dechairo Ph.D. | Chief Technology & Innovation Officer | 1973 |
| Mark A. Gardner M.B.A. | President | 1966 |
| Sabrina V. Dunbar | Director of Investor Relations & Communications | – |
| Heidi C. Chen J.D. | Chief Legal Officer | 1967 |
| Jami Biliboaca | Chief People Officer | – |
| Melanie Duquette | Chief Growth Officer | – |
| Lisa Gurry | Chief Business Officer | – |
| Linda Genen M.D., M.P.H. | Chief Medical Officer | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.